- Home
- CLDI vs FTEL Comparison
CLDI vs FTEL Comparison
Compare CLDI & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- FTEL
- Stock Information
- Founded
- CLDI 2014
- FTEL 2007
- Country
- CLDI United States
- FTEL Australia
- Employees
- CLDI N/A
- FTEL N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- FTEL
- Sector
- CLDI Health Care
- FTEL
- Exchange
- CLDI Nasdaq
- FTEL Nasdaq
- Market Cap
- CLDI 8.7M
- FTEL 9.1M
- IPO Year
- CLDI N/A
- FTEL 2023
- Fundamental
- Price
- CLDI $1.60
- FTEL $5.06
- Analyst Decision
- CLDI
- FTEL
- Analyst Count
- CLDI 0
- FTEL 0
- Target Price
- CLDI N/A
- FTEL N/A
- AVG Volume (30 Days)
- CLDI 141.6K
- FTEL 283.7K
- Earning Date
- CLDI 11-11-2025
- FTEL 04-28-2025
- Dividend Yield
- CLDI N/A
- FTEL N/A
- EPS Growth
- CLDI N/A
- FTEL N/A
- EPS
- CLDI N/A
- FTEL N/A
- Revenue
- CLDI N/A
- FTEL $4,990,695.00
- Revenue This Year
- CLDI N/A
- FTEL N/A
- Revenue Next Year
- CLDI N/A
- FTEL N/A
- P/E Ratio
- CLDI N/A
- FTEL N/A
- Revenue Growth
- CLDI N/A
- FTEL 29.02
- 52 Week Low
- CLDI $1.41
- FTEL $4.61
- 52 Week High
- CLDI $46.68
- FTEL $792.00
- Technical
- Relative Strength Index (RSI)
- CLDI 43.90
- FTEL 61.48
- Support Level
- CLDI $1.41
- FTEL $5.01
- Resistance Level
- CLDI $1.68
- FTEL $6.09
- Average True Range (ATR)
- CLDI 0.08
- FTEL 1.18
- MACD
- CLDI 0.05
- FTEL -0.05
- Stochastic Oscillator
- CLDI 66.74
- FTEL 30.32
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.